The risks and costs of life sciences product development have become so high that few companies are willing to bear them on their own. As partnerships become vital, skill in deal-making has become almost as vital as scientific acumen for today’s pharma and biotech firms. Insight into the deal market is crucial for companies seeking to design advantageous deals.

During this Lunch & Learn, Stephen Thau, creator of BioMeter – a quarterly deal report that tracks deal activity across different stages of product development and different indications – will discuss its findings through the first half of 2013.

Attendees of the program will gain:

• Insight into current market dynamics for licensing and collaboration deals
• Understanding of the value of licensing assets at different stages of development
• Understanding of market trends